Neurex Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurex Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ChinuSFO who wrote (326)	7/16/1997 5:23:00 PM
From: beach3	of 449

I got the news from www.thestreet.com. This is a pay service, but there is a free trial. I find it to be very useful. Jesse Eisinger, a reporter for thestreet.com is covering the Montgomery Securities Biotechnology Investors Conference in New York this week. He wrote: "In other news from the Montgomery conference Tuesday, Neurex (NXCO:Nasdaq) said it would not have to do further studies of Corlopam, a drug for high blood pressure in hospitalized patients, before the drug is approved. A Food and Drug Administration advisory panel late last month voted to recommend approval of the drug but said it wanted more data from Neurex on how Corlopam interacts with other medications. That led to a 25% decline in the stock over the next few days. Neurex now says it expects to launch the drug in the fourth quarter. The company's stock was trading at 13 1/2 midday, up 1/4."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next